Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinnov-Therapeutics Completes Recruitment of KT-110 Phase 2 Clinical Trial in Alcohol Dependence Disorders","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces USFDA Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Alpress LP

    Menu

    Alpress LP

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Alembic Pharmaceuticals Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alembic Pharmaceuticals Announces USFDA Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg

              Details:

              Prazosin hydrochloride inhibits the postsynaptic alpha-1 adrenoceptors. This inhibition blocks the vasoconstricting (narrowing) effect of catecholamines (epinephrine and norepinephrine) on the vessels, leading to peripheral blood vessel dilation.

              Lead Product(s): Prazosin Hydrochloride

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Prazosin Hydrochloride-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kinnov Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kinnov-Therapeutics Completes Recruitment of KT-110 Phase 2 Clinical Trial in Alcohol Dependence Disorders

              Details:

              KT-110, a new and innovative approach based on dual receptor targeting. Study evaluates the efficacy, safety and tolerance of KT-110, a combination of 2 molecules protected by a compositional patent, on alcohol consumption in patients suffering from severe alcoholism.

              Lead Product(s): Cyproheptadine Hydrochloride,Prazosin Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: KT-110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: ECSOR

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Nuray Prazosin HCL
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Close
              4
              Post Enquiry
              POST ENQUIRY